 |
The CEOs of top biopharma companies issued an extraordinary PR statement today to counter president Trump’s politicization of the COVID-19 pandemic crisis by rushing a COVID-19 vaccine to market.
The heads of AstraZeneca, BioNTech, GlaxoSmithKline, Moderna, Novavax, Pfizer, Sanofi, Johnson & Johnson and Merck pledged to “stand with science,” not political pressure to come up with a vaccine prior to the presidential election
They promised to seek approval of a vaccine only after its safety and efficacy has been established through a Phase 3 clinical study that is designed and conducted to meet the requirements of expert regulatory authorities such as FDA.
“We, the undersigned biopharmaceutical companies, want to make clear our on-going commitment to developing and testing potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles,” say the CEOs.
They reinstated their commitment to 1) “always make the safety and well-being of vaccinated individuals our top priority;” 2) “continue to adhere to high scientific and ethical standards regarding the conduct of clinical trials and the rigor of manufacturing processes;” and “work to ensure a sufficient supply and range of vaccine options, including those suitable for global access.”
The CEOs believe the pledge “will help ensure public confidence in the rigorous scientific and regulatory process by which COVID-19 vaccines are evaluated and may ultimately be approved.”
The statement follows last month’s announcement by Peter Marks, the FDA’s director for biologics evaluation and research, that he would quit if an unproven vaccine gets pushed out into the market.
On Sept. 7, Trump said a vaccine "will be very safe and very effective, and it will be delivered very soon” and that we “could even have it during the month of October."
The biopharma CEOs threw some cold water on that Trumpian fantasy.
The audacious autocrat who occupies the White House has achieved what was thought to be impossible. He has united the Hatfields and McCoys of the editorial world in opposition to his $1.776B slush fund... Sign of these sorry times: George Soros' Open Society Foundations plans to spend $300M to promote democracy and economic security in the US... PR play of the week goes to Steven Rosenbaum, author of “The Future of Truth."
Even the most effective communications team couldn't help Shein, which is renowned for its lousy human rights record, recoup its $100M outlay to acquire the beloved Everlane ethical fashion champion... College graduates are tired of baby boomers, such as former Google CEO Eric Schmidt, talking up the wonders of AI. They are the ones facing bleak job prospects.
Richard Nixon is remembered for his infamous "I am not a crook" statement. Donald Trump will be haunted by his "I don’t think about Americans’ financial situation” line... Nixon's trip to China changed the world. Trump's trip to China may also change the world, for the worse... Pity the president's PR team that denies reality to stay on the good side of their boss.
Nine percent of US adults think it was okay for Donald Trump to post an image depicting himself as Jesus Christ. Oh Lord!... It’s hard to shed a tear for a billionaire, especially one with a thin skin like Citadel chief Ken Griffin... A Republican group plans to support GOP candidates who want to restore foreign aid cuts made by Elon Musk's DOGE.
The death of Ted Turner, CNN's visionary founder, highlights the network's uncertain future under Paramount Skydance ownership... Anti-Defamation League reports a 33% drop in antisemitic incidents in 2025. But hold the cheers because 2025 was the third most violent year for American Jews... AI could use some PR according to Yale Youth Poll... Omnicom Media Intelligence warns that ad frequency can result in brand damage... Wall Street gives Bronx cheer to Coinbase's decision to fire about 700 people.
